2021
DOI: 10.1016/j.mehy.2020.110371
|View full text |Cite
|
Sign up to set email alerts
|

Blood clots in COVID-19 patients: Simplifying the curious mystery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
44
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 67 publications
(53 citation statements)
references
References 16 publications
3
44
0
Order By: Relevance
“…Damaging the endothelium causes the release of the von Willebrand factor (vWF), which activates blood platelets and neutrophils. Activated platelets additionally stimulate neutrophils to produce NETs, which become a structure upon which blood platelets, erythrocytes, and fibrines aggregate aiding the development of clots [ 38 , 41 , 42 , 43 , 44 ].…”
Section: Neutrophil Extracellular Trapsmentioning
confidence: 99%
“…Damaging the endothelium causes the release of the von Willebrand factor (vWF), which activates blood platelets and neutrophils. Activated platelets additionally stimulate neutrophils to produce NETs, which become a structure upon which blood platelets, erythrocytes, and fibrines aggregate aiding the development of clots [ 38 , 41 , 42 , 43 , 44 ].…”
Section: Neutrophil Extracellular Trapsmentioning
confidence: 99%
“…Blood clotting abnormalities in lungs and other organs in COVID-19 patients have been reported by several studies 92 . In autopsies of COVID-19 patients, thrombosis was found to be a prominent finding across multiple organs, even in spite of extensive anticoagulation treatment and regardless of timing of clinical progression, indicating that thrombosis might be at play in the early stages of disease 92 . One hypothesis to explain this observation is that the dysfunction of endothelial cells may play an important role in increased risk of thrombosis 93 .…”
Section: Discussionmentioning
confidence: 82%
“…Lusutrombopag is another antithrombocytopenic agent that binds to ACE2 in the PD region where the spike protein interacts. SARS-CoV-2-associated injury may initiate activation of coagulation and clotting cascades leading to the formation of internal blood clots [ 52 ]. Two anticoagulants eptifibatide and betrixaban dock onto the spike protein binding sites in ACE1 and ACE2, respectively.…”
Section: Discussionmentioning
confidence: 99%